Endoscopy Screening for Esophageal Cancer

Terminated

• Conditions: Head and Neck Cancer
• Interventions: Procedure: Endoscopy screening with narrow band imaging

• Registration Number: NCT00927446
• Lead Sponsor: Lotung Poh-Ai Hospital

Brief Summary

Patients with head and neck cancer frequently develop synchronous or metachronous esophageal malignancies. Previous studies have demonstrated the efficacy of endoscopic screening for esophageal cancer in head and neck cancer patients. The Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions. However, whether the application of NBI improves the detection results have not been critically evaluated.

This study aims to investigate the diagnostic value of the NBI system in the endoscopic screening for esophageal neoplastic lesions in patients with head and neck cancer.

Detailed Description

This is a prospective blinded controlled tandem endoscopy trial conducted in a regional medical center (Lotung Poh-Ai Hospital, Taiwan). Patients with tissue diagnosis of head and neck cancer are enrolled. Endoscopy screening for esophageal lesions is first performed by using the conventional white light system. Suspicious lesions are recorded. Then the entire esophagus is examined under the NBI system by another endoscopist, who is blinded to the result of the conventional endoscopy. After the endoscopic inspection completed, all suspicious lesions are biopsied. Before each procedure, which one of the two participating endoscopists applies the conventional or NBI system is randomized. The diagnostic rate of esophageal neoplasm by the conventional white light system and that of the NBI system are compared.

The endpoint is the neoplastic lesion detected on endoscopic biopsy. We considered invasive cancer, carcinoma in-situ, and high-grade dysplasia (which usually cannot be distinguished from carcinoma in situ) as the primary points. Any dysplastic lesions were considered as secondary points.

Study Timeline

• Study Start: 2009-06
• Study First Submitted: 2009-06-22
• Study First Submitted QC: 2009-06-24
• Study First Posted: 2009-06-25
• Primary Completion: 2010-04
• Study Completion: 2010-04
• Status Verified: 2010-10
• Last Update Submitted: 2010-10-18
• Last Update Posted: 2010-10-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• patients with tissue diagnosis of head and neck cancer
• histopathology of head and neck cancer is carcinoma (including squamous cell carcinoma, adenocarcinoma or undifferentiated)
• aged more than 18 years old
• agree to under go upper gastrointestinal endoscopy

Exclusion Criteria

• lack of written informed consent
• the origin of head and neck cancer is metastatic
• histopathology of head and neck cancer is not carcinoma (e.g., sarcoma, lymphoma, etc)
• incomplete upper gastrointestinal endoscopy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Endoscopy screening	Endoscopy screening with narrow band imaging	Patients with tissue diagnosis of head and neck cancer undergo endoscopy screening with conventional white light system first. Then the entire esophagus is examined under the NBI system by another endoscopist, who is blinded to the result of the conventional endoscopy.

Primary Outcome Measures

Name	Time	Method
Pathological interpretation of biopsy specimen for invasive cancer, carcinoma in-situ, or high-grade dysplasia	Within 3 days of endoscopy examination

Secondary Outcome Measures

Name	Time	Method
Pathological interpretation of biopsy specimen for any grade of dysplasia	within 3 days of endoscopy examination

Trial Locations

Locations (1)

Lotung Poh-Ai Hospital; 🇨🇳 Yilan, Taiwan